The Neurological Readiness Platform

The Brain Reveals Itself
Through the Eye.
Now We Can Read It.

ClearGazeTest measures 12 neurological biomarkers in 5 minutes using infrared video oculography — detecting concussion, TBI, real-time impairment, and early neurodegeneration across every major healthcare, safety, and defense market.

12
Quantitative
biomarkers
5 min
Complete
assessment
500 Hz
Binocular
sampling
7
Distinct
markets
185ms 0.91g
Saccadic Latency Smooth Pursuit Pupil Velocity Anti-Saccade Convergence Fixation Stability Contrast Sensitivity Scotopic Threshold
One Platform. Every Neurological Question.

The Eye Is a Window Into the Brain. We Built the Camera.

The oculomotor system — the neural machinery that controls eye movement — is the most neurologically dense sensorimotor system in the human body. It integrates input from the frontal cortex, cerebellum, brainstem, basal ganglia, vestibular nuclei, and autonomic nervous system in real time.

When any of those systems are disrupted — by trauma, fatigue, substance, disease, or medication — the eye movement record changes in quantifiable, reproducible ways. ClearGazeTest captures those changes with infrared video oculography at 500 Hz and translates them into 12 clinically actionable biomarkers in 5 minutes.

Real-Time Functional Assessment

Measures current neurological state — not past exposure. The question answered is "is this person impaired right now?" — which no blood or urine test can address.

🎯

Quantitative, Not Observational

Every result is a number — not a clinician's subjective impression. 182 ms saccadic latency is objective. "Looks a little slow" is not. Courts, regulators, and physicians need the former.

🔄

Longitudinal Baseline Architecture

Every assessment builds on the last. Individual baseline deviation is more sensitive than population norms alone — enabling detection of subtle change across a career, season, or treatment course.

▶ ClearGazeTest — Platform Specifications
Modality
Infrared Binocular VOG
Sampling Rate
500 Hz (both eyes, simultaneous)
Assessment Duration
~5 minutes, automated
Biomarkers
12 quantitative parameters
Normative Database
Age- & sex-stratified population
Baseline Architecture
Individual longitudinal tracking
Output Format
PDF report · HL7 FHIR · EHR export
Operator Requirement
No specialist required (MA / tech)
Compliance
HIPAA · SOC 2 · DoD-compatible
Non-invasive No radiation Portable Real-time results Court-defensible 5 min chair-side
Total Addressable Markets

Seven Markets. One Platform.

A single, scalable technology infrastructure addresses some of the most underserved neurological assessment needs across healthcare, safety, defense, and law.

$8.4B
Sports Concussion
Assessment Market
$3.8M
Sports concussions
reported annually (US)
$28B
Workplace impairment
annual economic cost
38
US states with legal
cannabis & no impairment test
413K+
Active duty TBI cases
requiring monitoring
Market Divisions

Every Major Neurological Assessment Gap. Addressed.

Each market represents a distinct, underserved need - unified by a single platform that speaks the language of each audience.

⚕️ Featured Market
🧠
Clinical Providers
Neurologists, sports medicine physicians, emergency medicine, occupational medicine, geriatricians, concussion clinic directors, and addiction medicine specialists. ClearGazeTest delivers quantitative oculomotor biomarkers with neural pathway attribution, normative comparison, and EHR integration — the objective neurological measurement clinicians have never had access to at chair-side.
Neurology Sports Medicine Emergency Medicine Occupational Medicine Geriatrics Addiction Medicine
🏈 Sports & Athletics
⛑️
Sports Concussion
High school, collegiate, and post-collegiate athletes. 3.8 million sports concussions annually — 50% unreported. ClearGazeTest enables objective baseline, real-time injury detection, and evidence-based return-to-play clearance. Replaces symptom self-report with quantitative neurological data.
High School Athletes Collegiate (D1–D3) Elite / Pro Return-to-Play
🎖 Veterans & First Responders
🪖
Veteran & First Responder TBI
400,000+ veterans with blast-related TBI, plus firefighters and law enforcement with occupational TBI exposure. The "invisible wound" — no imaging finding, no outward sign, but profound neurological disruption measurable through the eye movement record.
Combat Veterans Firefighters Law Enforcement Blast TBI
🚔 Law Enforcement & Traffic Safety
⚖️
Roadside Impairment Detection
Law enforcement, prosecutors, and traffic safety agencies face a historic gap: cannabis impairment cannot be measured by any validated field test. 38 states have legalized cannabis. 12.6M cannabis-impaired driving trips per year. ClearGazeTest is the court-defensible objective solution.
Law Enforcement Prosecutors Traffic Safety Cannabis Gap
🏭 Workplace & Industrial Safety
🔧
Workplace Impairment
Pilots, truckers, railroad operators, heavy equipment, nuclear, and transit. $81B annual cost of workplace impairment. Standard drug testing measures past exposure — not today's neurological fitness. ClearGazeTest answers the only question that matters to safety officers: is this person fit right now?
Aviation / FAA Trucking / FMCSA Railroad / FRA Nuclear / NRC
👴 Aging & Geriatric Care
🌿
Senior Brain Health
54 million Americans 65+. 1 in 4 falls annually — leading cause of TBI in this population. Oculomotor biomarkers detect neurodegenerative change years before cognitive symptoms appear. The platform enables annual baseline monitoring, fall risk assessment, medication safety evaluation, and early dementia detection.
Dementia Screening Fall Prevention Care Facilities Geriatrics
✈️ Military & Aviation
🎯
Military & Aviation Readiness
Active duty pilots, DoD aeromedical programs, FAA aviation medical examiners, and SOCOM. Pre-mission neurological readiness screening detects blast TBI, G-force cumulative effects, fatigue impairment, and NVG night-vision readiness gaps that no standard flight physical can measure. 5 minutes. Before wheels up.
USAF / USN / SOF FAA AME NVG Readiness Blast TBI
"Oculomotor assessment is the EKG of the brain - objective, real-time, and impossible to fake. Every major neurological condition leaves a signature in the eye movement record. We now have the technology to read it in 5 minutes."
- Scientific foundation of ClearGazeTest · Medical Card Exam
Protocol

Five Minutes. Twelve Biomarkers. One Clear Answer.

The same platform, the same protocol, the same technology — applied across every market in the ClearGazeTest suite.

1

Establish Baseline

Pre-season, pre-deployment, or first-visit calibration creates an individual neurological reference. Future assessments compare to personal baseline — far more sensitive than population norms alone.

2

5-Minute Assessment

Automated stimulus battery administered by non-specialist staff. No physician presence required. No patient preparation, no radiation, no discomfort. Results before the patient leaves the chair.

3

Automated Scoring

500 Hz infrared capture is processed algorithmically. All 12 biomarker values computed and ranked against individual baseline and age-stratified population norms. No manual scoring.

4

Actionable Report

Structured PDF with biomarker values, trend analysis, normative comparison, and plain-language summary. HL7 FHIR export for EHR integration. Designed for clinical, legal, and regulatory documentation.

Investor Overview

A Single Platform Addressing Multiple Billion-Dollar Market Gaps

ClearGazeTest represents a rare convergence: a validated scientific modality (oculomotor neuroscience), a scalable technology platform (infrared VOG), and a portfolio of underserved markets with urgent, documented, unmet needs.

Platform leverage: One technology investment addresses seven distinct verticals — healthcare, law enforcement, workplace safety, defense, geriatrics, and sports medicine. Each market generates independent revenue without requiring separate technology development.

Regulatory tailwind: Cannabis legalization across 38 states has created an acute enforcement and liability gap that no current technology addresses. ClearGazeTest is uniquely positioned as the objective impairment measurement solution that law, workplace policy, and clinical practice all require.

Defensible data moat: Every assessment adds to the longitudinal biomarker database. Population-level oculomotor data across clinical, occupational, and military populations creates a normative intelligence asset that compounds in value over time.

Clinical anchor: Medical Card Exam provides an established clinical partner for deployment, regulatory navigation, and physician-supervised implementation across markets requiring licensed medical oversight.

Recurrent revenue model: Per-assessment SaaS pricing across institutional clients (hospitals, sports organizations, employers, law enforcement agencies) creates predictable, recurring revenue at scale.

Request Investor Briefing →
$8.4B
Sports medicine & concussion assessment market
Sports
$81B
Annual US workplace impairment economic cost
Workplace
$50B
Annual US cost of fall-related injuries in adults 65+
Senior
$2.1B
DUI enforcement & impairment detection market
Law Enforcement
38
States with legal cannabis & zero validated impairment field test
Policy Gap
413K+
Active duty / veteran TBI patients requiring objective monitoring
Military / VA
7
Distinct verticals. One platform. No competing integrated solution.
Market Position
12
Biomarkers per assessment — each mapped to distinct neural circuits
Technology Depth
🏥
For Clinicians & Institutions

Request a Clinical Demo

Speak with a ClearGazeTest clinical specialist. See sample reports, discuss workflow integration, and learn how the platform serves your specific specialty and patient population.

Clinical Inquiry →
📈
For Investors & Partners

Investor Briefing

Explore the market opportunity, platform architecture, and growth strategy across all seven verticals. Contact our team at Medical Card Exam to schedule a confidential briefing.

Schedule Briefing →